微创心通医疗科技有限公司(“心通医疗”,股票代码:02160.HK)于2021年2月4日在香港联交所主板完成首次公开发行并上市,成为2021年首个依据上市规则18A章登陆香港联交所的医疗器械公司。本次发行募集资金总额约25.1亿港元(3.22亿美元)。通商律师事务所、盛德律师事务所担任发行人法律顾问;竞天公诚律师事务所、美国盛信律师事务所则为承销商提供法律意见。

心通医疗是中国领先的医疗器械企业之一,专注于心脏瓣膜疾病领域的创新性和潜在最优整体解决方案的研发和商业化。

盛德团队牵头律师为盛德全球管理委员会及执行委员会委员、亚太区管理合伙人蔡学雯律师和合伙人律师丁锰。

Sidley, STB act on MicroPort CardioFlow’s HK IPO

Sidley Austin and Commerce & Finance have advised MicroPort CardioFlow Medtech Corporation on its $322 million IPO, with Simpson Thacher & Bartlett and Jingtian & Gongcheng advising the underwriters.

MicroPort CardioFlow is a medical device company in China focusing on the research, development, and commercialisation of innovative transcatheter and surgical solutions for valvular heart diseases.

The Sidley team was led by Constance Choy, a member of Sidley’s Management Committee and Executive Committee and the managing partner for the Asia Pacific region, and partner Meng Ding.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.